Overview

Safety, Tolerability, PK, and Pharmacodynamics(PD) of IONIS APOCIII-LRx in Healthy Volunteers With Elevated Triglycerides

Status:
Completed
Trial end date:
2018-04-30
Target enrollment:
Participant gender:
Summary
The purpose is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of IONIS APOC-III-LRx given to healthy volunteer subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Ionis Pharmaceuticals, Inc.
Collaborator:
Akcea Therapeutics